FDC Limited (NSE: FDC) today announced its unaudited consolidated financial results for the second quarter and half-year ended September 30, 2026, showcasing robust growth across segments. The company’s revenue from operations for Q2 FY27 stood at Rs. 572 crores, a year-on-year increase of 21.0% over Rs. 473 crores in Q2 FY26. Domestic Formulations grew 22.6% Y-o-Y, led by Electral and Enerzal, while International Formulations grew 28.5% Y-o-Y in Q2 and 47.6% in H1 FY27.

Domestic Formulations Lead Growth

Domestic Formulations returned to double-digit growth in Q2 FY27, with revenue of Rs. 467 crores, up 22.6% Y-o-Y from Rs. 381 crores in Q2 FY26. The recovery was driven by flagship brands Electral and Enerzal, and Zifi, which overcame earlier quarter challenges.

International Formulations Continue Momentum

International Formulations continued their growth trajectory in Q2 FY27, with sales of Rs. 75 crores, up 28.5% Y-o-Y from Rs. 58 crores in Q2 FY26. For H1 FY27, International Formulations sales rose 47.6% Y-o-Y to Rs. 148 crores, from Rs. 101 crores in H1 FY26.

API Segment Sees Decline

The API business recorded sales of Rs. 28 crores in Q2 FY27, against Rs. 30 crores in Q2 FY26 (-4.8% Y-o-Y). For H1 FY27, API sales declined 4.0% Y-o-Y to Rs. 52 crores, from Rs. 54 crores in H1 FY26, mainly due to lower sales of one key molecule.

As a result, FDC Limited (NSE: FDC) is poised for continued growth, with a strong foundation in both domestic and international markets. The company remains committed to exploring innovative solutions and expanding its healthcare horizons globally.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of FDC Limited

FDC Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

FDC falls 15.2% over three months and has not found a floor yet. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 1.50 sits close to fair value. The stock is neither a clear buy nor obviously expensive. Buyers show up with 1.4x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 6.8% and profits at 13.2%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.50 premium is usually justified. Check Fundamentals of FDC Limited.

Mankind Pharma Limited (MANKIND) is set to host an Analyst/Investor Meet on October 2026, providing insights into its growth trajectory and strategic initiatives. The company, which has consistently demonstrated robust performance, will focus on its expansion in chronic and specialty divisions, hospital business, and consumer healthcare segments. With a revenue of ₹14,278 Cr in FY26, the company has shown an 18.1% Revenue CAGR from FY21 to FY26, underscoring its market leadership.

Growth Revival and Strategic Initiatives

The meet will highlight Mankind Pharma’s growth revival through its eight pillars of growth, including scaling branded specialty ACTx, expanding its hospital business, and focusing on good-to-great brands. The company has also made significant strides in consumer healthcare, becoming a leader in sexual wellness and expanding into consumer wellness with brands like Gas-O-Fast and Acne Star.

Future Outlook

Looking ahead, Mankind Pharma aims to deepen its penetration in high-barrier specialty brands and geographical expansion of key products in emerging markets. With a focus on high revenue growth and innovative bets, the company is poised to continue its impressive growth trajectory.

As a result of these strategic initiatives, Mankind Pharma is well-positioned to achieve its goal of becoming a global leader in pharmaceuticals.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Mankind Pharma Limited

Mankind Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Mankind falls 8.4% over three months and has not found a floor yet. The PEG reaches 3.22. The stock trades on brand and index weight, not on growth. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gains 1.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 17.7% and profits at 14.3% CAGR, with D/E of 0.58. Meanwhile, the stock dips 8.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Mankind Pharma Limited.

Indoco Remedies Limited (NSE: INDOCO) has announced that its Clinical Research Organisation, AnaCipher, has received approval from the National Health Surveillance Agency of Brazil (ANVISA) for both clinical and bioanalytical facilities. This approval, granted after an inspection conducted from March 30 to April 7, 2026, authorizes AnaCipher to conduct Bioavailability & Bioequivalence studies for submission to Brazil, along with associated bioanalytical support in accordance with ANVISA regulatory requirements.

Significance of the Approval

Commenting on this development, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “The approval reflects our CRO’s robust quality management systems, qualified scientific and clinical teams, validated analytical capabilities, and adherence to international regulatory and Good Clinical Practice standards. It reinforces our commitment to global quality standards and enhances our ability to support pharmaceutical companies in conducting studies for Brazil and expanding across Latin America.”

Strengthening Global Footprint

This approval further strengthens AnaCipher’s international regulatory footprint and reinforces its position as a trusted partner for global clinical research programmes. AnaCipher, headquartered in Hyderabad, India, provides bioequivalence and bioavailability studies, bioanalysis, clinical operations, regulatory affairs, data management, and biostatistics services to pharmaceutical companies worldwide. The CRO has been accredited by CDSCO, USFDA, WHO, EMA, UKMHRA, MoH -Oman, TPD -Canada, NMPA – China, MCC -South Africa, and MoH -Iraq.

As a fully integrated, research-oriented pharmaceutical company, Indoco Remedies Limited has a strong global presence with a turnover of US$ 175 million and a workforce of over 6000 employees, including over 300 skilled scientists and field staff. The company has 10 manufacturing facilities, supported by a state-of-the-art R&D Centre and a CRO facility, and its facilities have been approved by most regulatory authorities including USFDA and UK-MHRA.

For more details, visit www.anaciphercro.com and www.indoco.com.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indoco Remedies Limited

Indoco Remedies Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Indoco holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at only 3.0% and profits at 0.0% CAGR. In effect, the business treads water. The stock holds at 64% of its 52-week range with RSI at 51. In other words, neither side has a clear edge right now. The stock holds up despite 3.0% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Indoco Remedies Limited.